adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Company profile
Ticker
ADAP
Exchange
Website
CEO
Adrian Rawcliffe
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Adaptimmune Ltd
SEC CIK
Corporate docs
Subsidiaries
Adaptimmune Limited • Adaptimmune LLC • Adaptimmune B.V. • CM Intermediate Sub I, Inc. • CM Intermediate Sub II, Inc. • TCR² Therapeutics Inc. • TRUCS Therapeutics Limited • TRUC Securities Corporation ...
ADAP stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
22 Apr 24
8-K
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
12 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
PRE 14A
Preliminary proxy
1 Apr 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
6 Mar 24
8-K
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
27 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Feb 24
8-K
Other Events
31 Jan 24
8-K
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
4 Jan 24
Transcripts
ADAP
Earnings call transcript
2023 Q4
6 Mar 24
ADAP
Earnings call transcript
2023 Q3
8 Nov 23
ADAP
Earnings call transcript
2023 Q2
9 Aug 23
ADAP
Earnings call transcript
2023 Q1
12 May 23
ADAP
Earnings call transcript
2022 Q4
6 Mar 23
ADAP
Earnings call transcript
2022 Q3
8 Nov 22
ADAP
Earnings call transcript
2022 Q2
7 Aug 22
ADAP
Earnings call transcript
2022 Q1
9 May 22
ADAP
Earnings call transcript
2021 Q4
14 Mar 22
ADAP
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
SC 13D/A
New Enterprise Associates 14, L.P.
2 Apr 24
3
Initial statement of insider ownership
26 Mar 24
SC 13G/A
EcoR1 Capital, LLC
26 Mar 24
4
Cintia Piccina
18 Mar 24
SC 13G/A
Long Focus Capital Management, LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G
EcoR1 Capital, LLC
30 Jan 24
SC 13G/A
BAILLIE GIFFORD & CO
29 Jan 24
4
Adrian Rawcliffe
17 Jan 24
4
Elliot Norry
17 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 93.07 mm | 93.07 mm | 93.07 mm | 93.07 mm | 93.07 mm | 93.07 mm |
Cash burn (monthly) | (no burn) | (no burn) | 15.54 mm | 9.84 mm | 15.05 mm | 10.35 mm |
Cash used (since last report) | n/a | n/a | 105.87 mm | 67.05 mm | 102.52 mm | 70.47 mm |
Cash remaining | n/a | n/a | -12.80 mm | 26.02 mm | -9.45 mm | 22.60 mm |
Runway (months of cash) | n/a | n/a | -0.8 | 2.6 | -0.6 | 2.2 |
Institutional ownership, Q3 2023
39.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 163 |
Opened positions | 162 |
Closed positions | 0 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 5.62 tn |
Total shares | 60.25 mm |
Total puts | 137.50 k |
Total calls | 123.10 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 10.72 mm | $1.00 tn |
Artisan Partners Limited Partnership | 6.00 mm | $561.41 bn |
FMR | 5.14 mm | $480.96 bn |
T. Rowe Price Investment Management | 3.98 mm | $372.14 bn |
JHG Janus Henderson | 3.85 mm | $360.95 bn |
Westfield Capital Management | 3.80 mm | $356.04 bn |
Avoro Capital Advisors | 3.67 mm | $343.66 bn |
Wellington Management | 3.28 mm | $306.87 bn |
Capital International Investors | 2.17 mm | $203.05 bn |
T. Rowe Price | 1.64 mm | $152.97 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Cintia Piccina | Option to purchase Ordinary Shares Ordinary Shares | Grant | Acquire A | No | No | 0.0013 | 1,130,832 | 1.47 k | 1,130,832 |
18 Mar 24 | Cintia Piccina | Option to purchase Ordinary Shares Ordinary Shares | Grant | Acquire A | No | No | 0.25 | 5,088,864 | 1.27 mm | 5,088,864 |
17 Jan 24 | Bertrand William C JR | American Depositary Shares representing Ordinary Shares | Sell | Dispose S | No | No | 0.673 | 13,599 | 9.15 k | 20,201 |
17 Jan 24 | Bertrand William C JR | American Depositary Shares representing Ordinary Shares | Sell | Dispose S | No | No | 0.673 | 5,309 | 3.57 k | 7,785 |
17 Jan 24 | Elliot Norry | American Depositary Shares representing Ordinary Shares | Sell | Dispose S | No | No | 0.673 | 12,967 | 8.73 k | 19,257 |
17 Jan 24 | Elliot Norry | American Depositary Shares representing Ordinary Shares | Sell | Dispose S | No | No | 0.673 | 5,309 | 3.57 k | 7,785 |
17 Jan 24 | John Lunger | American Depositary Shares representing Ordinary Shares | Sell | Dispose S | No | No | 0.673 | 12,805 | 8.62 k | 19,015 |
17 Jan 24 | John Lunger | American Depositary Shares representing Ordinary Shares | Sell | Dispose S | No | No | 0.673 | 5,309 | 3.57 k | 7,785 |
16 Jan 24 | Bertrand William C JR | American Depositary Shares representing Ordinary Shares | Sell | Dispose S | No | No | 0.79 | 4,681 | 3.70 k | 7,023 |
16 Jan 24 | Elliot Norry | American Depositary Shares representing Ordinary Shares | Sell | Dispose S | No | No | 0.79 | 2,287 | 1.81 k | 3,363 |
News
12 Health Care Stocks Moving In Friday's After-Market Session
19 Apr 24
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
8 Mar 24
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
8 Mar 24
Adaptimmune Therapeutics Q4 EPS $(0.04) Beats $(0.10) Estimate, Sales $231.00K May Not Be Comparable To $20.47M Estimate
6 Mar 24
Earnings Scheduled For March 6, 2024
6 Mar 24